GRT-R902

GRT-R902 is a cancer vaccine developed by Seattle Project. The sponsor describes its target as patient-specific neoantigens, which OnCo does not yet have a target page for. The sponsor states: A patient-specific neoantigen cancer vaccine boost (30 micrograms, intramuscular, given four times over the first year) used after the GRT-C901 prime, as part of a heterologous prime/boost regimen with checkpoint inhibition to generate T-cell responses against patient-specific tumour mutations. ClinicalTrials.gov describes the intervention as: A patient-specific neoantigen cancer vaccine boost, administered via IM injection at a dose of 30ug 4 times over the course of the first year. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05141721 (A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer), in colorectal cancer. The largest, NCT05141721, plans to enrol 700 participants with primary completion expected 2027-03. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.